Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro
Anna Gidari, Samuele Sabbatini, Elisabetta Schiaroli, et al.
Microorganisms (2022) Vol. 10, Iss. 7, pp. 1475-1475
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients
Małgorzata Mikulska, Chiara Sepulcri, Chiara Dentone, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 2, pp. 280-286
Open Access | Times Cited: 93
SARS-CoV-2 Drug Resistance and Therapeutic Approaches
Sania Batool, Santosh Chokkakula, Ju Hwan Jeong, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41980-e41980
Open Access | Times Cited: 3
Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics
Daniele Focosi, Scott A. McConnell, Shmuel Shoham, et al.
International Journal of Antimicrobial Agents (2023) Vol. 61, Iss. 2, pp. 106708-106708
Open Access | Times Cited: 31
Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature
Davide Marangoni, Roberta Maria Antonello, Marco Coppi, et al.
International Journal of Infectious Diseases (2023) Vol. 133, pp. 53-56
Open Access | Times Cited: 27
Early combination therapy of COVID-19 in high-risk patients
Hans Martin Orth, Charlotte Flasshove, Moritz Berger, et al.
Infection (2023) Vol. 52, Iss. 3, pp. 877-889
Open Access | Times Cited: 21
Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2
Jessica Wagoner, Shawn Herring, Tien-Ying Hsiang, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 5
Open Access | Times Cited: 34
Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques
Kyle Rosenke, Matt C. Lewis, Friederike Feldmann, et al.
JCI Insight (2022) Vol. 8, Iss. 4
Open Access | Times Cited: 30
A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients
Claudia Alteri, Valeria Fox, Rossana Scutari, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 22
Synergistic Activity of Remdesivir–Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report
Anna Gidari, Samuele Sabbatini, Elisabetta Schiaroli, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1577-1577
Open Access | Times Cited: 13
Stabilization of the Dimeric State of SARS-CoV-2 Main Protease by GC376 and Nirmatrelvir
Alessandro Paciaroni, Valeria Libera, Francesca Ripanti, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6062-6062
Open Access | Times Cited: 11
Viral target and metabolism‐based rationale for combined use of recently authorized small molecule COVID‐19 medicines: Molnupiravir, nirmatrelvir, and remdesivir
Daisy Yan, Bingfang Yan
Fundamental and Clinical Pharmacology (2023) Vol. 37, Iss. 4, pp. 726-738
Open Access | Times Cited: 10
Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?
Anna Gidari, Samuele Sabbatini, Sabrina Bastianelli, et al.
Viruses (2024) Vol. 16, Iss. 3, pp. 354-354
Open Access | Times Cited: 3
An Overview on Anti-COVID-19 Drug Achievements and Challenges Ahead
Mehdi Valipour, Hamid Irannejad, Hossein Keyvani
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 9, pp. 1248-1265
Open Access | Times Cited: 9
Recent updates on the biological efficacy of approved drugs and potent synthetic compounds against SARS-CoV-2
Anjani, Sumit Kumar, Brijesh Rathi, et al.
RSC Advances (2023) Vol. 13, Iss. 6, pp. 3677-3687
Open Access | Times Cited: 8
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants
Lia Fiaschi, Camilla Biba, Ilenia Varasi, et al.
(2024)
Open Access | Times Cited: 2
The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19
Rebekah Penrice-Randal, Eleanor G. Bentley, Parul Sharma, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Further preclinical characterization of molnupiravir against SARS-CoV-2: Antiviral activity determinants and viral genome alteration patterns
Paul-Rémi Petit, Franck Touret, Jean‐Sélim Driouich, et al.
Heliyon (2024) Vol. 10, Iss. 10, pp. e30862-e30862
Open Access | Times Cited: 2
Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: A narrative review
Paul Kinsella, Michael A. Moso, C. Orla Morrissey, et al.
Transplant Infectious Disease (2024) Vol. 26, Iss. 3
Open Access | Times Cited: 2
Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study
Davide Fiore Bavaro, Lucia Diella, Alessandra Belati, et al.
Viruses (2023) Vol. 15, Iss. 5, pp. 1199-1199
Open Access | Times Cited: 7
Combined Molnupiravir and Nirmatrelvir Treatment Improves the Inhibitory Effect on SARS-CoV-2 in Rhesus Macaques
Kyle Rosenke, Matt C. Lewis, Friederike Feldmann, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 10
The hope and hype of ellagic acid and urolithins as ligands of SARS-CoV-2 Nsp5 and inhibitors of viral replication
Elisa Bianconi, Anna Gidari, Maria Souma, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 5
Functional assessments of SARS-CoV-2 single-round infectious particles with variant-specific spike proteins on infectivity, drug sensitivity, and antibody neutralization
Wen‐Chi Su, Zan-Yu Chen, Young-Sheng Chang, et al.
Antiviral Research (2023) Vol. 220, pp. 105744-105744
Closed Access | Times Cited: 5
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants
Lia Fiaschi, Camilla Biba, Ilenia Varasi, et al.
Viruses (2024) Vol. 16, Iss. 2, pp. 168-168
Open Access | Times Cited: 1
Early combination therapy of COVID-19 in high-risk patients
Hans Martin Orth, Charlotte Flasshove, Moritz Berger, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 2
Targeted degrader technologies as prospective SARS-CoV-2 therapies
Rabia Khurshid, Joseph M. Schulz, Jiaming Hu, et al.
Drug Discovery Today (2023) Vol. 29, Iss. 1, pp. 103847-103847
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top